Fragmin Stungulyf, lausn 10.000 anti-Xa IU/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

fragmin stungulyf, lausn 10.000 anti-xa iu/ml

pfizer aps - dalteparinum natricum inn - stungulyf, lausn - 10.000 anti-xa iu/ml

Fragmin Stungulyf, lausn í áfylltri sprautu 10.000 anti-Xa IU Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

fragmin stungulyf, lausn í áfylltri sprautu 10.000 anti-xa iu

pfizer aps - dalteparinum natricum inn - stungulyf, lausn í áfylltri sprautu - 10.000 anti-xa iu

Fragmin Stungulyf, lausn í áfylltri sprautu með nálarvörn 10.000 and-Xa a.e. Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

fragmin stungulyf, lausn í áfylltri sprautu með nálarvörn 10.000 and-xa a.e.

pfizer aps - dalteparinum natricum inn - stungulyf, lausn í áfylltri sprautu með nálarvörn - 10.000 and-xa a.e.

RescueFlow Stungulyf/innrennslislyf, lausn 60/75 g/l Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

rescueflow stungulyf/innrennslislyf, lausn 60/75 g/l

oresund pharma aps - dextran 70; sodium chloride - stungulyf/innrennslislyf, lausn - 60/75 g/l

Uniferon Stungulyf, lausn 200 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

uniferon stungulyf, lausn 200 mg/ml

pharmacosmos a/s* - ferri hydroxidum dextran komplex - stungulyf, lausn - 200 mg/ml

Syntocinon Stungulyf, lausn 10 a.e./ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

syntocinon stungulyf, lausn 10 a.e./ml

alfasigma s.p.a. - oxytocinum inn - stungulyf, lausn - 10 a.e./ml

Suiseng Diff/A Evrópusambandið - íslenska - EMA (European Medicines Agency)

suiseng diff/a

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - svín - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Byfavo Evrópusambandið - íslenska - EMA (European Medicines Agency)

byfavo

paion deutschland gmbh - remimazolam besilate - meðvitandi sedation - psycholeptics - remimazolam is indicated in adults for procedural sedation. remimazolam 50 mg is indicated in adults for intravenous induction and maintenance of general anaesthesia.

Iasibon Evrópusambandið - íslenska - EMA (European Medicines Agency)

iasibon

pharmathen s.a. - ibandrónsýra - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - lyf til að meðhöndla beinsjúkdóma - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. meðferð æxli völdum álíka með eða án meinvörp. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

Recarbrio Evrópusambandið - íslenska - EMA (European Medicines Agency)

recarbrio

merck sharp & dohme b.v.  - imipenem einhýdrat, cílastatín járn, relebactam einhýdrat - gramm-neikvæð bakteríusýkingum - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 og 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4 og 5. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.